David Dodds

Dr. Dodds was most recently Director of Fermentation & Biocatalysis Development with Bristol-Myers Squibb. He previously held a position at Sepracor in its start-up phase, and was in charge of enzyme catalysis development. This work ultimately produced a number of patents on the enzymatic resolution of NSAIDs and Diltiazem. He subsequently joined Schering-Plough to help establish their biocatalysis group, before joining Bristol-Myers Squibb. He has been involved in multiple aspects of drug manufacturing, including chemical and fermentation process development molecular biology and microbiology and the development of intellectual property in these areas. He has a B.Sc. in Biochemistry, a M.Sc. in Biological Chemistry, a Ph.D. in Organic Synthesis, all from the University of Toronto.